Yoko Kaneko

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

NAK is an IκB kinase-activating kinase

Yuichiro Tojima, Atsushi Fujimoto, Mireille Delhase et al. · Nature · 2000 · 374 citations

Life Sciences, Biochemistry, Molecular Biology +7

Role of Human Cds1 (Chk2) Kinase in DNA Damage Checkpoint and Its Regulation by p53

Kaoru Tominaga, Hirobumi Morisaki, Yoko Kaneko et al. · Journal of Biological Chemistry · 1999 · 98 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +16

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study

Tsutomu Takeuchi, Yoshiya Tanaka, Koichi Amano et al. · Lara D. Veeken · 2011 · 89 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9